Vertex to Announce Fourth Quarter 2020 Financial Results
Listen to the webcast on February 1st at 4:30 p.m. EST
U.S. FDA Approves Label Expansions for Three of Our Cystic Fibrosis Medicines
Hemoglobinopathies Data Update and New Publication
With our partner CRISPR Therapeutics, we presented data on our investigational CRISPR/Cas9 gene-editing program for severe Hemoglobinopathies at the American Society of Hematology (ASH) and a new publication in the New England Journal of Medicine (NEJM)
Vertex Forward: Our Focus on Hemoglobinopathies
See how we’re researching potential gene-editing approaches for sickle cell disease and beta thalassemia
Featured contents
We Are Vertex